Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Wow

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Feb 10, 2023 12:44am

64 Views

Post# 35278802

RE:RE:Wow

Unlike Lee - I also believe the share price is super important to Andrew. There is a reason why he has something like 15-20M shares. He has intel that none of us know. Private $hit that only board members have. So he is on a mission to drive shareholders value up, by A LOT. Why? Because he will be the biggest beneficiary.

$2-5 in 2023.
$5-30 once the device and RCH-01 commercialize.

I think they should sell RCH-01 rights to a suitor for $1.5B

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages